摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-甲氧基-1-甲基-2-萘甲醛 | 812690-19-0

中文名称
7-甲氧基-1-甲基-2-萘甲醛
中文别名
——
英文名称
7-methoxy-1-methyl-naphthalene-2-carbaldehyde
英文别名
7-Methoxy-1-methyl-2-naphthaldehyde;7-methoxy-1-methylnaphthalene-2-carbaldehyde
7-甲氧基-1-甲基-2-萘甲醛化学式
CAS
812690-19-0
化学式
C13H12O2
mdl
——
分子量
200.237
InChiKey
LLPLUDSTJOLOST-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.15
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    7-甲氧基-1-甲基-2-萘甲醛 在 palladium 10% on activated carbon 叔丁基过氧化氢依布硒盐酸 作用下, 以 叔丁醇二氯甲烷 为溶剂, 反应 7.5h, 生成 7-甲氧基-1-甲基-2-萘甲酸
    参考文献:
    名称:
    [EN] AMIDE DERIVATIVES AS SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS
    [FR] DERIVES D'AMIDE EN TANT QU'INHIBITEURS SELECTIFS DU RECAPTAGE DE LA SEROTONINE
    摘要:
    本发明涉及式(I)的化合物,其中R1从以下选项中选择:(a) (C1-C6)烷基,可选地被1-3个取代基取代,每个取代基独立地从以下选项中选择:(i) CF3,OH,(C1-C6)烷基,(C3-C6)环烷基,(C1-C6)烷氧基和卤素;(ii) 苯基,可选地与苯基或环己基融合,所述苯基或融合苯基可选地被1-3个取代基取代,所述取代基独立地从(C1-C6)烷基,(C1-C6)烷基酯,OH和卤素中选择;和(b) (C3-C6)环烷基,可选地与(C5-C7)环烷基融合,所述环烷基或融合环烷基可选地被OH,(C1-C6)烷基,(C1-C6)烷氧基和卤素取代。R2为苯基,可选地融合到(C4-C6)环烷基,苯基或吡啶基,所述苯基或融合苯基基团可选地被1-3个取代基取代,每个取代基独立地从(C1-C6)烷基,(C1-C6)烷氧基,卤素和OH中选择。n为1至2,以及其药学上可接受的盐、溶剂化合物或多形体;但是当n为2且R1为2-(3,4-二甲氧基苯基)-1-乙基,3,3-二苯基-1-丙基或2,4-二氟苯基时,R2不能为4-三氟甲氧基苯基,2,4,6-三甲氧基苯基,4-乙酰氧基苯基或2,4-二氟苯基;这些是一类选择性5-羟色胺再摄取抑制剂(SSRIs)。
    公开号:
    WO2004111003A1
  • 作为产物:
    描述:
    2-formyl-7-methoxy-1-naphthyl trifluoromethanesulfonate 在 四(三苯基膦)钯 三甲基环三硼氧烷potassium carbonate 作用下, 以 1,4-二氧六环 为溶剂, 反应 8.0h, 生成 7-甲氧基-1-甲基-2-萘甲醛
    参考文献:
    名称:
    [EN] AMIDE DERIVATIVES AS SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS
    [FR] DERIVES D'AMIDE EN TANT QU'INHIBITEURS SELECTIFS DU RECAPTAGE DE LA SEROTONINE
    摘要:
    本发明涉及式(I)的化合物,其中R1从以下选项中选择:(a) (C1-C6)烷基,可选地被1-3个取代基取代,每个取代基独立地从以下选项中选择:(i) CF3,OH,(C1-C6)烷基,(C3-C6)环烷基,(C1-C6)烷氧基和卤素;(ii) 苯基,可选地与苯基或环己基融合,所述苯基或融合苯基可选地被1-3个取代基取代,所述取代基独立地从(C1-C6)烷基,(C1-C6)烷基酯,OH和卤素中选择;和(b) (C3-C6)环烷基,可选地与(C5-C7)环烷基融合,所述环烷基或融合环烷基可选地被OH,(C1-C6)烷基,(C1-C6)烷氧基和卤素取代。R2为苯基,可选地融合到(C4-C6)环烷基,苯基或吡啶基,所述苯基或融合苯基基团可选地被1-3个取代基取代,每个取代基独立地从(C1-C6)烷基,(C1-C6)烷氧基,卤素和OH中选择。n为1至2,以及其药学上可接受的盐、溶剂化合物或多形体;但是当n为2且R1为2-(3,4-二甲氧基苯基)-1-乙基,3,3-二苯基-1-丙基或2,4-二氟苯基时,R2不能为4-三氟甲氧基苯基,2,4,6-三甲氧基苯基,4-乙酰氧基苯基或2,4-二氟苯基;这些是一类选择性5-羟色胺再摄取抑制剂(SSRIs)。
    公开号:
    WO2004111003A1
点击查看最新优质反应信息

文献信息

  • Amide derivatives as selective serotonin re-uptake inhibitors
    申请人:Andrews David Mark
    公开号:US20050014789A1
    公开(公告)日:2005-01-20
    The present invention relates to compounds of formula (I), wherein R 1 is selected from: (a) (C 1 -C 6 )alkyl, optionally substituted by 1-3 substituents, each independently selected from: (i) CF 3 , OH, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 1 -C 6 )alkoxy and halo. (ii) Phenyl, optionally fused with phenyl or cyclohexyl, said phenyl or fused phenyl optionally substituted with 1-3 groups selected from (C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl ester, OH and halo; and (b) (C 3 -C 6 )cycloalkyl, optionally fused with (C 5 -C 7 )cycloalkyl, said cycloalkyl or fused cycloalkyl optionally substituted by OH, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy and halo. R 2 is Phenyl, optionally fused to (C 4 -C 6 )cycloalkyl, phenyl or pyridyl, said phenyl or fused phenyl moiety optionally substituted with 1-3 groups each independently selected from (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, halo and OH; n is 1 to 2; and pharmaceutically acceptable salts, solvates or polymorphs thereof; With the proviso that when n is 2 and R 1 is 2-(3,4-dimethoxylphenyl)-1-ethyl, 3,3-diphenyl-1-propyl or 2,4-difluorophenyl, then R 2 cannot be 4-trifluoromethoxyphenyl, 2,4,6-trimethoxyphenyl, 4-acetoxyphenyl or 2,4-difluorophenyl; which are a class of selective serotonin re-uptake inhibitors (SSRIs).
    本发明涉及式(I)的化合物,其中R1选自:(a)(C1-C6)烷基,可选地被1-3个取代基取代,每个取代基独立地选自:(i)CF3,OH,(C1-C6)烷基,(C3-C6)环烷基,(C1-C6)烷氧基和卤素;(ii)苯基,可选地与苯基或环己基融合,所述苯基或融合苯基可选地被1-3个选自(C1-C6)烷基,(C1-C6)烷酯,OH和卤素的基团取代;和(b)(C3-C6)环烷基,可选地与(C5-C7)环烷基融合,所述环烷基或融合环烷基可选地被OH,(C1-C6)烷基,(C1-C6)烷氧基和卤素取代。R2为苯基,可选地融合到(C4-C6)环烷基、苯基或吡啶基上,所述苯基或融合苯基基团可选地被1-3个独立选自(C1-C6)烷基,(C1-C6)烷氧基,卤素和OH的基团取代;n为1到2;以及其药学上可接受的盐、溶剂或多型性;但当n为2且R1为2-(3,4-二甲氧基苯基)-1-乙基、3,3-二苯基-1-丙基或2,4-二氟苯基时,则R2不能是4-三氟甲氧基苯基、2,4,6-三甲氧基苯基、4-乙酰氧基苯基或2,4-二氟苯基;这是一类选择性5-羟色胺再摄取抑制剂(SSRI)。
  • N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALIN RE-UPTAKE INHIBITORS
    申请人:Pfizer Limited
    公开号:EP1828122A2
    公开(公告)日:2007-09-05
  • [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
    申请人:PFIZER LTD
    公开号:WO2006064351A2
    公开(公告)日:2006-06-22
    [EN] A compound of Formula (I) and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein: R1 is H, C1-6alkyl, -C(A)Y, C3-8cycloalkyl, aryl, het, aryl-C1-4alkyl or het-Cl-4alkyl, wherein the cycloalkyl, aryl or het groups are optionally substituted; A is S or O; Y is H, C1-6alkyl, aryl, het, aryl-C1-4alkyl or het­-C1-4alkyl; aryl is independently selected from phenyl, naphthyl, anthracyl or phenanthryl; het is independently selected from an aromatic or non-aromatic 4-, 5- or 6- membered heterocycle which contains at least one N, O or S heteroatom, optionally fused to a 5- or 6- membered carbocyclic group or a second 4-, 5- or 6-membered heterocycle which contains at least one N, O or S heteroatom; R2 is aryl1 or het1, each optionally substituted; aryl1 is independently selected from phenyl, naphthyl, anthracyl, phenanthryl, or indanyl; het1 is an aromatic 5 to 10 membered heterocyclic ring system which contains at least one N, O or S heteroatom, optionally containing an aryl group; R3 is H, C1-8alkyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-6alkyl, C1-8alkylSC1-8alkyl, het3, or het3-C1-4alkyl, wherein the alkyl, cycloalkyl and het3 groups are each optionally substituted; het3 is a non-aromatic 4-, 5- or 6- membered heterocycle which contains at least one N, O or S heteroatom, optionally fused to a 5- or 6- membered carbocyclic group or a second 4-, 5- or 6-membered heterocycle which contains at least one N, O or S heteroatom; or R3 is (CH2)a ,K
    [FR] L'invention porte sur un composé représenté par la formule (I) et sur ses produits dérivés acceptables sur le plan pharmaceutique et/ou vétérinaire dans laquelle R1 est H, C1-6alkyl, -C(A)Y, C3.8cycloalkyl, aryl, het, aryl-C1-,alkyl ou het-Cl.4alkyl, les groupes cycloalkyle, aryle ou het étant éventuellement substitués; A est S ou O; Y est H, C1-6alkyl, aryl, het, aryl-CI.4alkyl ou het-C1_4alkyl; aryle est sélectionné indépendamment parmi phényle, naphthyle, anthracyle ou phénanthryle; het est sélectionné indépendamment parmi un hétérocycle aromatique ou non aromatique à 4, 5 ou 6 chaînons qui contient au moins un hétéroatome N, O ou S éventuellement fusionné à un groupe carbocyclique à 5 ou 6 chaînons ou un deuxième hétérocycle à 4, 5 ou 6 chaînons qui contient au moins un hétéroatome N, O ou S. R2 est aryl1 ou het1, chacun éventuellement substitué; aryl1 est sélectionné indépendamment parmi phényle, naphthyle, anthracyle, phénanthryle ou indanyle; het1 est un système de noyau hétérocyclique aromatique de 5 à 10 chaînons qui contient au moins un hétéroatome N, O or S, contenant éventuellement un groupe aryle; R3 est H, C1_8alkyl, C3_8cycloalkyl, C3- 8cycloalkyl-C1-6alkyl, C1-3alkylSC1-8alkyl, het3 ou het3-C1.4alkyl, les groupes alkyle, cycloalkyle et het3 étant chacun éventuellement substitués, het3 est un hétérocycle non aromatique à 4, 5 ou 6 chaînons qui contient au moins un hétéroatome N, O ou S, éventuellement fusionné à un groupe carbocyclique à 5 ou 6 chaînons ou un deuxième hétérocycle à 4, 5 ou 6 chaînons qui contient au moins un hétéroatome N, O ou S ; ou R3 est (CH2)a ,K
  • [EN] AMIDE DERIVATIVES AS SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS<br/>[FR] DERIVES D'AMIDE EN TANT QU'INHIBITEURS SELECTIFS DU RECAPTAGE DE LA SEROTONINE
    申请人:PFIZER LTD
    公开号:WO2004111003A1
    公开(公告)日:2004-12-23
    The present invention relates to compounds of formula (I), wherein R1 is selected from: (a) (C1-C6)alkyl, optionally substituted by 1-3 substituents, each independently selected from: (i) CF3, OH, (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkoxy and halo; (ii) Phenyl, optionally fused with phenyl or cyclohexyl, said phenyl or fused phenyl optionally substituted with 1-3 groups selected from (C1-C6)alkyl, (C1-C6)alkyl ester, OH and halo; and (b) (C3-C6)cycloalkyl, optionally fused with (C5-C7)cycloalkyl, said cycloalkyl or fused cycloalkyl optionally substituted by OH, (C1-C6)alkyl, (C1-C6)alkoxy and halo. R2 is Phenyl, optionally fused to (C4-C6)cycloalkyl, phenyl or pyridyl, said phenyl or fused phenyl moiety optionally substituted with 1-3 groups each independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, halo and OH. n is 1 to 2 and pharmaceutically acceptable salts, solvates or polymorphs thereof; With the proviso that when n is 2 and R1 is 2-(3,4-dimethoxylphenyl)-1-ethyl, 3,3­diphemyl-1-propyl or 2,4-difluorophenyl, then R2 cannot be 4-trifluoromethoxyphenyl, 2,4,6-trimethoxyphenyl, 4-acetoxyphenyl or 2,4-difluorophenyl; which are a class of selective serotonin re-uptake inhibitors (SSRIs).
    本发明涉及式(I)的化合物,其中R1从以下选项中选择:(a) (C1-C6)烷基,可选地被1-3个取代基取代,每个取代基独立地从以下选项中选择:(i) CF3,OH,(C1-C6)烷基,(C3-C6)环烷基,(C1-C6)烷氧基和卤素;(ii) 苯基,可选地与苯基或环己基融合,所述苯基或融合苯基可选地被1-3个取代基取代,所述取代基独立地从(C1-C6)烷基,(C1-C6)烷基酯,OH和卤素中选择;和(b) (C3-C6)环烷基,可选地与(C5-C7)环烷基融合,所述环烷基或融合环烷基可选地被OH,(C1-C6)烷基,(C1-C6)烷氧基和卤素取代。R2为苯基,可选地融合到(C4-C6)环烷基,苯基或吡啶基,所述苯基或融合苯基基团可选地被1-3个取代基取代,每个取代基独立地从(C1-C6)烷基,(C1-C6)烷氧基,卤素和OH中选择。n为1至2,以及其药学上可接受的盐、溶剂化合物或多形体;但是当n为2且R1为2-(3,4-二甲氧基苯基)-1-乙基,3,3-二苯基-1-丙基或2,4-二氟苯基时,R2不能为4-三氟甲氧基苯基,2,4,6-三甲氧基苯基,4-乙酰氧基苯基或2,4-二氟苯基;这些是一类选择性5-羟色胺再摄取抑制剂(SSRIs)。
查看更多